Adherence, Diversion, & Misuse

This CDC page provides an overview of how opioid use impacts pregancy to help women who use opioids during pregnancy be aware of the possible risks and potential treatment options for opioid use disorder.

These reports and detailed tables present estimates from the 2019 National Survey on Drug Use and Health (NSDUH), specifically pertaining to substance use among women.

This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This guideline develops a framework to evaluate existing clinical practice guidelines for prescribing opioids for acute pain indications and recommends indications for which new evidence-based guidelines should be developed.

This two-day public workshop convened regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines.

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).

This was a two-day virtual public workshop (which can now be re-watched) that convened regulators, clinical researchers, providers, patient advocates, and other stakeholders to exchange information and obtain input by discussing prescriber education's potential role in alleviating the evolving opioid and substance use crisis.

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.